InCarda Gets $30m Closer To Inhalable AF Drug/Device Therapy
Executive Summary
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.